Javascript must be enabled to continue!
Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis
View through CrossRef
Mpox (earlier known as monkeypox) virus infection is a recognized public health emergency. There has been little research on the treatment options. This article reviews the specific drugs used to treat mpox virus infection and the vaccines used here. Instead of focusing on the mechanistic basis, this review narrates the practical, real-life experiences of individual patients of mpox virus disease being administered these medicines. We conducted a bibliometric analysis on the treatment of the mpox virus using data from several databases like PubMed, Scopus, and Embase. The research on this topic has grown tremendously recently but it is highly concentrated in a few countries. Cidofovir is the most studied drug. This is because it is indicated and also used off-label for several conditions. The drugs used for mpox virus infection include tecovirimat, cidofovir, brincidofovir, vaccinia immune globulin, and trifluridine. Tecovirimat is used most frequently. It is a promising option in progressive mpox disease in terms of both efficacy and safety. Brincidofovir has been associated with treatment discontinuation due to elevated hepatic enzymes. Cidofovir is also not the preferred drug, often used because of the unavailability of tecovirimat. Trifluridine is used topically as an add-on agent along with tecovirimat for ocular manifestations of mpox virus disease. No study reports individual patient data for vaccinia immune globulin. Though no vaccine is currently approved for mpox virus infection, ACAM 2000 and JYNNEOS are the vaccines being mainly considered. ACAM 2000 is capable of replicating and may cause severe adverse reactions. It is used when JYNNEOS is contraindicated. Several drugs and vaccines are under development and have been discussed alongside pragmatic aspects of mpox virus treatment and prevention. Further studies can provide more insight into the safety and efficacy of Tecovirimat in actively progressing mpox virus disease.
Frontiers Media SA
Muhammad Aaqib Shamim
Prakisini Satapathy
Bijaya Kumar Padhi
Sai Dutt Veeramachaneni
Naushaba Akhtar
Anindita Pradhan
Abhimanyu Agrawal
Pradeep Dwivedi
Aroop Mohanty
Keerti Bhusan Pradhan
Russell Kabir
Ali A. Rabaan
Jawaher Alotaibi
Zainab A. Al Ismail
Zainab Ahmed Alsoliabi
Ali Al Fraij
Ranjit Sah
Alfonso J. Rodriguez-Morales
Title: Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis
Description:
Mpox (earlier known as monkeypox) virus infection is a recognized public health emergency.
There has been little research on the treatment options.
This article reviews the specific drugs used to treat mpox virus infection and the vaccines used here.
Instead of focusing on the mechanistic basis, this review narrates the practical, real-life experiences of individual patients of mpox virus disease being administered these medicines.
We conducted a bibliometric analysis on the treatment of the mpox virus using data from several databases like PubMed, Scopus, and Embase.
The research on this topic has grown tremendously recently but it is highly concentrated in a few countries.
Cidofovir is the most studied drug.
This is because it is indicated and also used off-label for several conditions.
The drugs used for mpox virus infection include tecovirimat, cidofovir, brincidofovir, vaccinia immune globulin, and trifluridine.
Tecovirimat is used most frequently.
It is a promising option in progressive mpox disease in terms of both efficacy and safety.
Brincidofovir has been associated with treatment discontinuation due to elevated hepatic enzymes.
Cidofovir is also not the preferred drug, often used because of the unavailability of tecovirimat.
Trifluridine is used topically as an add-on agent along with tecovirimat for ocular manifestations of mpox virus disease.
No study reports individual patient data for vaccinia immune globulin.
Though no vaccine is currently approved for mpox virus infection, ACAM 2000 and JYNNEOS are the vaccines being mainly considered.
ACAM 2000 is capable of replicating and may cause severe adverse reactions.
It is used when JYNNEOS is contraindicated.
Several drugs and vaccines are under development and have been discussed alongside pragmatic aspects of mpox virus treatment and prevention.
Further studies can provide more insight into the safety and efficacy of Tecovirimat in actively progressing mpox virus disease.
Related Results
Monkeypox Post COVID19: Knowledge, Worrying, and Vaccine Adoption of the Arabic General Population
Monkeypox Post COVID19: Knowledge, Worrying, and Vaccine Adoption of the Arabic General Population
Abstract
Background
The outbreak of monkeypox was designated a global public health emergency by the World Health Organization ...
Monkeypox Vaccines: Current Update
Monkeypox Vaccines: Current Update
Monkeypox belonging to the genus Orthopoxvirus (OPV) of the family poxviridiae poses a major human threat even after 30 years after eradicating smallpox. OPV family includes other ...
Monkeypox: In Quest of Effective Vaccines
Monkeypox: In Quest of Effective Vaccines
Purpose: The main objective of the study includes various aspects of monkeypox, its biology andtransmutability that are relevant for risk assessment and preparedness for a monkeypo...
Tatalaksana Monkeypox
Tatalaksana Monkeypox
Monkeypox merupakan penyakit zoonosis akibat virus yang terjadi terutama di daerah hutan hujan tropis Afrika tengah dan barat. Virus monkeypox mirip cacar. Meskipun monkeypox jauh ...
Monkeypox Virus: A potential concern for Pakistan?
Monkeypox Virus: A potential concern for Pakistan?
Dear Madam, the sudden emergence of the monkeypox virus occurred in 1970, after which it firmly anchored its roots in 11 countries in the African region. The virus belongs to the s...
In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs
In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs
Abstract
The World Health Organization (WHO) recently declared the monkeypox outbreak ‘A public health emergency of international concern’. The monkeypox virus belongs to t...
Can Artificial Intelligence Detect Monkeypox from Digital Skin Images?
Can Artificial Intelligence Detect Monkeypox from Digital Skin Images?
Abstract
An outbreak of Monkeypox has been reported in 75 countries so far, and it is spreading at a fast pace around the world. The clinical attributes of Monkeypo...

